Strategic Impact

By targeting a tumor’s metabolic entry point rather than downstream signaling alone, MTX-101 represents a differentiated approach in precision oncology.

We aim to disrupt tumor fuel acquisition—directly, selectively, and clinically meaningfully.

We believe cancer can be treated more effectively by targeting how it feeds and grows.

Our vision is to develop smarter, more precise medicines that cut off the fuel cancer cells depend on—while minimizing harm to healthy cells.

By focusing on the unique metabolic weaknesses of tumors, we aim to create treatments that are not only innovative, but truly life-changing for patients and their families.